FDA partners with Aetion to gather real-world data on the coronavirus
The FDA continues its investment in real-world data with this partnership.
Legal/Regulatory
Pricing remdesivir: Will Gilead profit from the COVID-19 treatment?
As remdesivir emerges as an effective coronavirus treatment, how Gilead prices the drug will face heightened scrutiny.
Telehealth rules relaxed, but patients still face barriers
The government has relaxed telehealth rules as most people stay home to help flatten the curve, but patients still face barriers for virtual visits.
FDA drug reviews chug along during coronavirus, but for how long?
The FDA said drug and device reviews are continuing at the normal rate, but warned that may not be able to continue indefinitely as the pandemic drags on.
Government, researchers and big tech team up for digital COVID-19 tools
Apple, Facebook and Verily are working on digital tools to help track infections and inform the public about the virus.
COVID-19 vaccine collides with drug price fervor
Three pharma companies launch the first human clinical trials of experimental COVID-19 drugs and vaccines.
Coronavirus isn’t the only thing on FDA’s mind
Drugs are still being approved and reports are still churning out, all while the FDA battles the COVID-19 outbreak.
FDA takes additional action to expedite availability of COVID-19 tests
The Food and Drug Administration has announced that it will not object to the New York State Department of Health authorizing certain laboratories in New York to start testing patients for coronavirus disease 2019 once the tests have been validated.
FDA provided a CBD update, but little new information
The FDA said its focus going forward was education, research and enforcement.
Trump and officials meet with pharma on coronavirus treatments
President Trump wanted to know how quickly pharma could have a vaccine or treatment ready for public use.
